Comparison of the efficacy between conbercept and ranibizumab in the treatment of wet macular degeneration

Objective To compare the efficacy between intravitreal injection conbercept and ranibizumab in the treatment of wet age-related macular degeneration(AMD). Methods The clinical data of 40 eyes of 40 patients with wet AMD from Feb. 2017 to Aug. 2018 in this hospital were analyzed retrospectively. Group A, 20 eyes of 20 cases, received conbercept and group B, 20 eyes of 20 cases, received ranibizumab. All patients underwent intravitreal injection once a month for three consecutive times.The follow-up time was 3 months. Results The visual acuity at 1 week, 1 and 3 months after intravitreal injection was better than that before injection (P 0.05). There was no significant difference between the two groups at different time after injection (P=0.839, 0.402, 0.849). Central macular thickness were decreased in both groups after injection compared with that before injection (P<0.05), but the difference between the two groups was not statistically significant (P=0.885, 0.476, 0.634). Choroidal thickness of the two groups decreased after injection (P<0.05), but the difference between the two groups was not statistically significant (P=0.280, 0.831, 0.093). Conclusion Intravitreal injection of conbercept or ranibizumab can improve visual acuity, ameliorate macular structure, and decrease choroidal thickness for the treatment of wet age-related macular degeneration. There is no significant difference between the two drugs. Key words: Degeneration, macular, age-related, wet; Conbercept, Ranibizumab, intravitreal injection; Efficacy, clinical